{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:09Z","timestamp":1793214609614,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ophtha.2013.09.048","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:30:38Z","timestamp":1387240238000},"page":"785-796.e3","source":"Crossref","is-referenced-by-count":408,"title":["Expert Panel Recommendations for the Use of Anti\u2013Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders"],"prefix":"10.1016","volume":"121","author":[{"given":"Grace","family":"Levy-Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Jabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell W.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell N.","family":"Van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2013.09.048_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/bmj.328.7430.39","article-title":"Assessing the quality of research","volume":"328","author":"Glasziou","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2013.09.048_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1108\/09526869910297331","article-title":"Auditing the implementation of SIGN (Scottish Intercollegiate Guidelines Network) clinical guidelines","volume":"12","author":"Keaney","year":"1999","journal-title":"Int J Health Care Qual Assur Inc Leadersh Health Serv"},{"key":"10.1016\/j.ophtha.2013.09.048_bib5","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib6","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1529-8019.2009.01258.x","article-title":"Is there truly a risk of lymphoma from biologic therapies?","volume":"22","author":"Dommasch","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib8","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2013.09.048_bib9","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib10","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib11","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2013.09.048_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2013.09.048_bib15","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's Disease","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2013.09.048_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Beh\u00e7et's disease\u2014review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib18","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et's disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Beh\u00e7et's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ophtha.2013.09.048_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-2008-1027361","article-title":"Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital","volume":"225","author":"Petropoulos","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2013.09.048_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/bjo.2009.168856","article-title":"Timing of recurrent uveitis in patients with Beh\u00e7et's disease receiving infliximab treatment","volume":"95","author":"Yamada","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A\u00a0single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et's disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et's disease [letter]?","volume":"66","author":"van Laar","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.09.048_bib30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis","volume":"31","author":"Takase","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ophtha.2013.09.048_bib31","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Beh\u00e7et's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib32","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","article-title":"Adalimumab for the treatment of Beh\u00e7et's disease: experience in 19 patients","volume":"51","author":"Perra","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl","key":"10.1016\/j.ophtha.2013.09.048_bib33","first-page":"S54","article-title":"Efficacy of adalimumab in patients with Beh\u00e7et's disease unsuccessfully treated with infliximab","volume":"29","author":"Olivieri","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl","key":"10.1016\/j.ophtha.2013.09.048_bib34","first-page":"S93","article-title":"Efficacy of switching to adalimumab in a patient with refractory uveitis of Beh\u00e7et's\u00a0disease to infliximab [letter]","volume":"29","author":"Leccese","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib35","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10067-008-0857-5","article-title":"Efficacy of etanercept in the treatment of a patient with Beh\u00e7et's disease","volume":"27","author":"Curigliano","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib37","first-page":"729","article-title":"Successful treatment of resistant Beh\u00e7et's disease with etanercept [letter]","volume":"23","author":"Atzeni","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaad.2004.11.031","article-title":"A\u00a0case of mucocutaneous Beh\u00e7et's disease responding to etanercept [letter]","volume":"52","author":"Sommer","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/41.10.1213-b","article-title":"Beh\u00e7et's syndrome: response to infliximab after failure of etanercept [letter]","volume":"41","author":"Estrach","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Infliximab for juvenile idiopathic arthritis-associated uveitis","volume":"33","author":"Richards","year":"2005","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib42","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib43","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","article-title":"Biological response modifier therapy for refractory childhood uveitis","volume":"91","author":"Gallagher","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib44","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/rheumatology\/ken298","article-title":"Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis","volume":"47","author":"Simonini","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ajo.2007.08.018","article-title":"Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up","volume":"144","author":"Ardoin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Tynjala","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","article-title":"Adalimumab therapy for childhood uveitis","volume":"149","author":"Vazquez-Cobian","year":"2006","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ophtha.2013.09.048_bib49","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"Diaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib50","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/art.11155","article-title":"Long-term outcome of etanercept therapy in children with treatment-refractory uveitis [letter]","volume":"48","author":"Reiff","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib51","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A\u00a0randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib54","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents","volume":"149","author":"Saurenmann","year":"2006","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ophtha.2013.09.048_bib56","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib57","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis","volume":"66","author":"Tynjala","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.09.048_bib59","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib60","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","article-title":"Prevention of flare recurrences in childhood refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab","volume":"63","author":"Simonini","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib61","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/kes212","article-title":"Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease\u2013a case cohort interventional study","volume":"51","author":"Sen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib62","doi-asserted-by":"crossref","unstructured":"Simonini G, Taddio A, Cattalini M, et\u00a0al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J [serial online] 2013;11:16. Available at: http:\/\/www.ped-rheum.com\/content\/11\/1\/16. Accessed September 28,\u00a02013.","DOI":"10.1186\/1546-0096-11-16"},{"key":"10.1016\/j.ophtha.2013.09.048_bib63","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","article-title":"Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Heiligenhaus","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ophtha.2013.09.048_bib64","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.09.048_bib65","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib66","first-page":"201","article-title":"A\u00a0double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ophtha.2013.09.048_bib67","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00296-007-0359-9","article-title":"Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab","volume":"27","author":"Cruz","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ophtha.2013.09.048_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5414\/CPP43007","article-title":"Infliximab in chronic ocular inflammation","volume":"43","author":"Baughman","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib69","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ophtha.2013.09.048_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ophtha.2013.09.048_bib71","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10384-009-0691-6","article-title":"Uveitis associated with sarcoidosis exacerbated by etanercept therapy [letter]","volume":"53","author":"Suzuki","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib72","first-page":"645","article-title":"Sarcoid-related uveitis occurring during etanercept therapy","volume":"21","author":"Hashkes","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib73","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1365-4632.2009.04080.x","article-title":"Facial granulomatous nodules during etanercept treatment for psoriasis [letter]","volume":"48","author":"Samimi","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib74","first-page":"471","article-title":"Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases","volume":"26","author":"Toussirot","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib75","first-page":"648","article-title":"Sarcoid-like granulomatous disease following etanercept treatment for RA [letter]","volume":"34","author":"Kudrin","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib76","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/art.22238","article-title":"Development of sarcoidosis during etanercept therapy","volume":"55","author":"Gonzalez-Lopez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib77","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10384-008-0652-5","article-title":"Treating refractory scleritis with infliximab [letter]","volume":"53","author":"Ahn","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09273940802023786","article-title":"Biologic response modifier therapy for psoriatic ocular inflammatory disease","volume":"16","author":"Huynh","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2013.09.048_bib79","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bjo.2006.111666","article-title":"The use of infliximab in ocular inflammation","volume":"92","author":"Prendiville","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.eye.6701457","article-title":"The successful use of infliximab in resistant relapsing polychondritis and associated scleritis [letter]","volume":"19","author":"Cazabon","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib81","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib82","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3129\/i09-061","article-title":"Infliximab for the treatment of active scleritis [report online]","volume":"44","author":"Sen","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib83","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/j.1755-3768.2009.01546.x","article-title":"Regression of necrotizing scleritis in Wegener's granulomatosis after infliximab treatment [letter][report online]","volume":"88","author":"Kontkanen","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2013.09.048_bib85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2013.09.048_bib86","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial [letter]","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib87","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A\u00a0prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib88","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2012.05.048","article-title":"Infliximab treatment of patients with birdshot retinochoroidopathy","volume":"120","author":"Artornsombudh","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/09273940802204527","article-title":"Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome","volume":"16","author":"Wang","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2013.09.048_bib90","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3109\/09273941003739910","article-title":"Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab","volume":"18","author":"Khalifa","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2013.09.048_bib91","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/bjo.2008.153981","article-title":"Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease [letter]","volume":"93","author":"Niccoli","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib92","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab)","volume":"19","author":"Benitez-del-Castillo","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib93","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1111\/j.1755-3768.2009.01738.x","article-title":"Infliximab in serpiginous choroiditis [letter][report online]","volume":"88","author":"Seve","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib94","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial","volume":"97","author":"Suhler","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib95","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, et\u00a0al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med [serial online] 2009;6(7):e1000097. Available at: http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.1000097. Accessed September 28,\u00a02013.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"10.1016\/j.ophtha.2013.09.048_bib96","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2011.0042","article-title":"Cytokines in autoimmune uveitis","volume":"31","author":"Horai","year":"2011","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.ophtha.2013.09.048_bib97","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.autrev.2010.10.002","article-title":"Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation","volume":"10","author":"Commodaro","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ophtha.2013.09.048_bib98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12026-008-8031-3","article-title":"Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells","volume":"42","author":"Caspi","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.ophtha.2013.09.048_bib99","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2013.09.048_bib100","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","article-title":"Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists","volume":"151","author":"Mohler","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib101","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.4049\/jimmunol.151.11.6602","article-title":"Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice","volume":"151","author":"Wooley","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib102","first-page":"1444","article-title":"Identification of the lymphokines, interferon-gamma and interleukin-2, in inflammatory eye diseases","volume":"29","author":"Hooks","year":"1988","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.048_bib103","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3121\/cmr.4.4.248","article-title":"Cytokines in uveitis","volume":"4","author":"van Laar","year":"2006","journal-title":"Clin Med Res"},{"key":"10.1016\/j.ophtha.2013.09.048_bib104","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/j.ophtha.2013.09.048_bib105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib106","first-page":"917","article-title":"Aqueous humor interleukin-6 levels in uveitis","volume":"31","author":"Murray","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl","key":"10.1016\/j.ophtha.2013.09.048_bib107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/02713689208999531","article-title":"Cytokines in human intraocular inflammation","volume":"11","author":"Franks","year":"1992","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2013.09.048_bib108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-3083.1992.tb01645.x","article-title":"Ocular and systemic determination of IL-1 beta and tumour necrosis factor in a patient with ocular inflammation","volume":"11","author":"Palexas","year":"1992","journal-title":"Scand J Immunol Suppl"},{"key":"10.1016\/j.ophtha.2013.09.048_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1506s53","article-title":"Experimental autoimmune uveoretinitis in the rat and mouse","author":"Caspi","year":"2003","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib110","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/eji.1830260510","article-title":"Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina","volume":"26","author":"Dick","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib111","first-page":"3884","article-title":"The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice","volume":"35","author":"Nakamura","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.048_bib112","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1167\/iovs.02-1156","article-title":"Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis","volume":"44","author":"Robertson","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.048_bib113","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/intimm\/10.6.807","article-title":"IL-10 has a protective role in experimental autoimmune uveoretinitis","volume":"10","author":"Rizzo","year":"1998","journal-title":"Int Immunol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib114","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4049\/jimmunol.161.1.122","article-title":"Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis","volume":"161","author":"Tarrant","year":"1998","journal-title":"J\u00a0Immunol"},{"issue":"Pt 2","key":"10.1016\/j.ophtha.2013.09.048_bib115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/eye.1997.53","article-title":"T\u00a0cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile","volume":"11","author":"Caspi","year":"1997","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2013.09.048_bib116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.12-10138","article-title":"Effects of systemic and intravitreal TNF-alpha inhibition in experimental autoimmune uveoretinitis","volume":"54","author":"Busch","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.048_bib117","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.4049\/jimmunol.158.12.5997","article-title":"IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response","volume":"158","author":"Jones","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib118","first-page":"64","article-title":"Interleukin-6 does not mediate endotoxin-induced uveitis in mice: studies in gene deletion animals","volume":"39","author":"Rosenbaum","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.048_bib119","first-page":"2408","article-title":"Tumor necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice","volume":"25","author":"Rosenbaum","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/expr.1996.0117","article-title":"TNF-alpha and genetic susceptibility to parasitic disease","volume":"84","author":"Goldfeld","year":"1996","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib121","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568010023344535","article-title":"TNFalpha as therapeutic target: new drugs, more applications","volume":"1","author":"Reimold","year":"2002","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"10.1016\/j.ophtha.2013.09.048_bib122","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0300-483X(02)00225-1","article-title":"Enhancement of TNF-alpha expression does not trigger apoptosis upon exposure of glial cells to lead and lipopolysaccharide","volume":"178","author":"Cheng","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib123","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0889-857X(05)70028-4","article-title":"Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis","volume":"24","author":"Kavanaugh","year":"1998","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ophtha.2013.09.048_bib124","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0952-7915(00)00167-9","article-title":"Novel, non-antigen-specific therapeutic approaches to autoimmune\/inflammatory diseases","volume":"12","author":"Illei","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib125","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib126","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0889-857X(05)70211-8","article-title":"Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis","volume":"27","author":"Keystone","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ophtha.2013.09.048_bib127","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2012.05.004","article-title":"Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients","volume":"42","author":"Thyagarajan","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MJT.0b013e31820b8846","article-title":"Tuberculosis infections and tumor necrosis factor alpha antagonists","volume":"20","author":"Gan","year":"2013","journal-title":"Am J Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib129","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib130","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00417-007-0549-x","article-title":"Tuberculous uveitis after treatment with etanercept","volume":"245","author":"Fonollosa","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib131","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib132","first-page":"2557","article-title":"Induction of autoantibodies during prolonged treatment with infliximab","volume":"30","author":"Louis","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib133","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jbspin.2008.12.008","article-title":"Anti-TNFalpha blockers, autoantibodies and autoimmune diseases","volume":"76","author":"Caramaschi","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ophtha.2013.09.048_bib134","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2009.09331.x","article-title":"Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test","volume":"161","author":"Laffitte","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2007.03553.x","article-title":"Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease","volume":"27","author":"Theis","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib136","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ibd.21362","article-title":"Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease","volume":"17","author":"Beigel","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ophtha.2013.09.048_bib137","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib138","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib139","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/ar2562","article-title":"Developments in the scientific and clinical understanding of the spondyloarthritides","volume":"11","author":"Sieper","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib140a","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/art.23440","article-title":"Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et\u00a0al","volume":"58","author":"Scrivo","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib141","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/art.23442","article-title":"Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et\u00a0al","volume":"58","author":"Sfikakis","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib142","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/art.23441","article-title":"Link between tumor necrosis factor inhibitors and onset of uveitis: comment on the article by Lim et\u00a0al","volume":"58","author":"Sheane","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib143","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents","volume":"149","author":"Saurenmann","year":"2006","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ophtha.2013.09.048_bib144","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.ophtha.2013.09.048_bib145","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s10067-009-1154-7","article-title":"Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy","volume":"28","author":"Bouchra","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib146","first-page":"645","article-title":"Sarcoid-related uveitis occurring during etanercept therapy","volume":"21","author":"Hashkes","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib147","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.ophtha.2013.09.048_bib148","doi-asserted-by":"crossref","first-page":"I65","DOI":"10.1136\/ard.58.2008.i65","article-title":"Etanercept: therapeutic use in patients with rheumatoid arthritis","volume":"58","author":"Garrison","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.09.048_bib149","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0016-5085(99)70294-5","article-title":"The relationship between infliximab treatment and lymphoma in Crohn's disease","volume":"117","author":"Bickston","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib150","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib151","first-page":"732","article-title":"Biologics in inflammatory disease: infliximab associated risk of lymphoma development","volume":"54","author":"Bucher","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.ophtha.2013.09.048_bib152","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5694\/j.1326-5377.2009.tb02435.x","article-title":"Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease","volume":"190","author":"Burger","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.ophtha.2013.09.048_bib153","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1529-8019.2009.01258.x","article-title":"Is there truly a risk of lymphoma from biologic therapies?","volume":"22","author":"Dommasch","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib154","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.09.048_bib155","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ophtha.2013.09.048_bib156","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2013.09.048_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2008.04.035","article-title":"Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib158","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib159","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ophtha.2013.09.048_bib160","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/112067210901900521","article-title":"Intravitreal infliximab in experimental endotoxin-induced uveitis","volume":"19","author":"Hosseini","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib161","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00417-008-0967-4","article-title":"Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit","volume":"247","author":"Theodossiadis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib162","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1167\/iovs.07-0932","article-title":"A\u00a0pilot study on ocular safety of intravitreal infliximab in a rabbit model","volume":"49","author":"Giansanti","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.09.048_bib163","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/IAE.0b013e3181d3758a","article-title":"Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis","volume":"30","author":"Farvardin","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2013.09.048_bib164","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/jop.2011.0199","article-title":"Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis","volume":"28","author":"Farvardin","year":"2012","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib165","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/jop.2012.0203","article-title":"Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group","volume":"29","author":"Wu","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2013.09.048_bib166","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/IAE.0b013e3181e9f942","article-title":"Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy","volume":"30","author":"Arias","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2013.09.048_bib167","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10792-012-9559-8","article-title":"Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group","volume":"32","author":"Wu","year":"2012","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib168","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","article-title":"intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2013.09.048_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0b013e3181cde727","article-title":"More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial","volume":"30","author":"Pulido","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2013.09.048_bib170","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2006.11.025","article-title":"Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis","volume":"143","author":"Woreta","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib171","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","article-title":"Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss","volume":"143","author":"Thorne","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib172","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2006.05.016","article-title":"Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis","volume":"113","author":"Kump","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.09.048_bib173","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Infliximab for juvenile idiopathic arthritis-associated uveitis","volume":"33","author":"Richards","year":"2005","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib174","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2010.79","article-title":"Pathogenesis of ankylosing spondylitis","volume":"6","author":"Tam","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ophtha.2013.09.048_bib175","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.09.048_bib176","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9394(86)90001-2","article-title":"Ocular involvement in chronic sarcoidosis","volume":"102","author":"Jabs","year":"1986","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642013008932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642013008932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T22:28:04Z","timestamp":1688855284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642013008932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":176,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0161642013008932"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.048","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718215532.793494993","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}